Chargement en cours...
Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability
ZL277 is a prodrug of belinostat with enhanced bioavailability and efficacy as a pan histone deacetylase (HDAC) inhibitor. In this study, we investigated the metabolism and pharmacokinetics of ZL277 in liver S9 fractions, liver microsomes, liver cytosol, and in mice. Metabolic products were identifi...
Enregistré dans:
| Publié dans: | Pharmaceuticals (Basel) |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6958523/ https://ncbi.nlm.nih.gov/pubmed/31817969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph12040180 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|